Loading…
← CockpitCompetitor Analysis › 3774.HK Fameglow Holdings LimitedOpen in the cockpit ↗

Fameglow Holdings Limited3774.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical/Nursing Services

Hong Kong-listed healthcare/nursing services company; specific service line not confirmed with confidence.

Mkt cap
$4.54B
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$2.74M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+19.7 pp
WACC 5.6%
Hurdle
+9 pp
Req g minus delivered
Close · HKDHK$43.46
1D+3.5%
1W+5.1%
1M+45.5%
3M+205.6%
6Mn/a
YTDn/a
1Yn/a
ATR %12.0%
52w lowhigh7.8% off high

What Fameglow does

Hong Kong-listed healthcare/nursing services company; specific service line not confirmed with confidence.

Where it sits in the supply chain

  • Health Care
  • Medical/nursing services

Moat: none

Headquarters: Hong Kong · Employees: 467

Fameglow at a glance

Size Fameglow (3774.HK) is a Hong Kong Health Care company (Medical/Nursing Services) with a market value of $4.54B, the 265th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$43.46 on 18 Nov 2026.

Growth Revenue grew 35.5% over the last twelve months (peer median +11.7%); the operating margin is 11.1% (peer median 9.0%).

Valuation It trades at 60.4× enterprise value to sales against a peer median of 2.2× (most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 57% a year for seven years (Req g). Recent delivered growth is +48%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 19.7 points above its cost of capital (5.6% WACC).

Fameglow financials

Reported figures in HKD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$590MHK$590MHK$435MHK$299MHK$228M
Revenue growth—+35%+45%+32%—
Gross profitHK$219MHK$218MHK$170MHK$122MHK$78.7M
EBITDAHK$146MHK$146MHK$114MHK$90.6MHK$64.3M
Net incomeHK$54.6MHK$54.6MHK$45.7MHK$40.8MHK$16.4M
Free cash flown/aHK$45.1MHK$26.2MHK$18.3MHK$38.1M
Capital expendituren/aHK$68.1MHK$53.4MHK$13.5MHK$32.2M
Total debtn/aHK$119MHK$92.4MHK$45.5MHK$66.4M

Quarterly statements and history in the cockpit →

Fameglow competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×60×BLLNOPCHHIMSLFSTCONMCOV-BRDNTLALPATHLABSHL002044AVAHDVAAGARWALEYE3774.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Fameglow is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%BLLNOPCHLFSTCONMCOV-BRDNTLALPATHLABSHLMDALIF-BAZTAENSGAGARWALEYE3774.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Fameglow is the large dot.

Fameglow competitors and peer comparison

How Fameglow compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Fameglow against its 20 peers (data as of 18 Nov 2026)
Measure3774.HKPeer medianRank in peer set
1-month return+45.5%+2.8%highest of 21
Distance from 52-week high-7.8%-12.9%6th highest of 21
Revenue growth (TTM)+35.5%+11.7%2nd highest of 21
Operating margin11.1%9.0%8th highest of 21
EV / Sales60.4×2.2×most expensive of 21
Growth the price implies (Req g, 7 yrs)57.4%12.7%most demanding of 18
Growth delivered (Del g)+48.4%+13.2%2nd highest of 18
Hurdle (Req g minus delivered)+9.0 pp-1.5 pp5th most demanding of 18
ROIC minus cost of capital+19.7 pp-0.2 pp2nd highest of 21
Net debt / EBITDA0.1×2.9×5th least indebted of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Fameglow 3774.HKHong Kong$4.54Bn/a+36%11%60.4×57.4%+48.4%
BillionToOne BLLNUnited States$4.37B+7%+72%10%9.1×22.8%+71.9%
Option Care Health OPCHUnited States$4.75B+43%+4%6%1.0×2.0%+13.2%
Hims & Hers Health HIMSUnited States$4.00B-26%+30%-1%1.7×n/an/a
Lifestance Health LFSTUnited States$5.24B+79%+23%6%3.3×33.4%+30.4%
Concentra Group Holdings Parent CONUnited States$5.31B+65%+12%17%3.2×3.6%+7.9%
Medicover MCOV-B.STSweden$3.87B+21%+3%7%2.0×19.6%+20.2%
RadNet RDNTUnited States$5.66B+32%+21%5%3.1×38.8%+13.7%
Dr. Lal PathLabs LALPATHLAB.NSIndia$3.53B+15%+17%24%10.4×32.3%+11.8%
Acadia Healthcare ACHCUnited States$3.49B+56%+4%10%1.8×n/an/a
Sonic Healthcare SHL.AXAustralia$6.87B+6%+14%9%1.4×9.1%+3.5%
Meinian Onehealth Healthcare 002044.SZChina$2.60B-27%-4%9%2.2×4.2%+5.7%
Pediatrix Medical MDUnited States$2.41B+37%+2%12%1.3×-4.4%+2.0%
Aveanna Healthcare AVAHUnited States$2.37B+41%+17%12%1.4×7.7%+10.2%
Addus HomeCare ADUSUnited States$2.25B+29%+12%11%1.5×4.0%+13.2%
AddLife ALIF-B.STSweden$2.13B+15%+2%8%2.5×21.1%+14.6%
Azenta AZTAUnited States$2.03B+162%+5%-2%2.8×38.0%+3.9%
DaVita DVAUnited States$10.2B-18%+6%15%1.7×-2.5%+3.4%
NeoGenomics NEOUnited States$1.98B+72%+11%-6%2.9×n/an/a
Ensign ENSGUnited States$10.7B+3%+17%9%2.2×12.7%+16.5%
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%7.8×43.0%+26.9%

Questions

Which companies are Fameglow's closest peers?
The cockpit's peer set: BillionToOne (BLLN), Option Care Health (OPCH), Hims & Hers Health (HIMS), Lifestance Health (LFST), Concentra Group Holdings Parent (CON), Medicover (MCOV-B.ST), RadNet (RDNT), Dr. Lal PathLabs (LALPATHLAB.NS).
Is Fameglow expensive compared with its peers?
On ev / sales it trades at 60.4× against a peer median of 2.2×, most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 57% a year for seven years (Req g). Recent delivered growth is +48%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.